Flavonoid alkaloids extracted from Polygonatum cyrtonema and extraction method and application thereof
Through permeable extraction and multi-stage extraction and separation of ethanol-aqueous solution of chicken head polina, flavonoid alkaloids with inhibiting α-glucosidase activity and antioxidant effects, solving the incomplete extraction of flavonoid alkaloids in the prior art Problem, achieving drug development for diabetes treatment and antioxidant.
Patent Information
- Application Number
- CN202211154055.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-21
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2042-09-21
AI Technical Summary
The prior art research on extracts from Polygonatum genus Polygonatum is not comprehensive enough, especially the extraction and application of flavonoid alkaloids has not been fully developed, and it cannot effectively inhibit the activity of α-glucosidase and provide antioxidant effects.
Polygonatum and ethanol-aqueous solution were mixed for permeation extraction, followed by extraction by petroleum ether, ethyl acetate and n-butanol, separated by silica gel column, gel column and reverse phase column to obtain the activity of inhibiting α-glucosidase and Flavonoid alkaloids with antioxidant capacity.
Six new flavonoids were successfully extracted, which had the ability to inhibit α-glucosidase activity and strongly scavenge ABTS free radicals, and could be used to prepare drugs for treating or preventing diabetes and antioxidants.
Smart Images

Figure CN116239581B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to plant extraction, and in particular to flavonoid alkaloids extracted from polygonatum cyrtonema and an extraction method and application thereof. Background Art
[0002] Polygonatum sibiricum Red. is a plant of the genus Polygonatum in the Liliaceae family. According to the 2020 edition of the "Chinese Pharmacopoeia", Polygonatum has the effects of tonifying qi and nourishing yin, strengthening the spleen, moistening the lungs, and benefiting the kidneys. It is used for spleen and stomach qi deficiency, fatigue, insufficient stomach yin, dry mouth and poor appetite, lung deficiency and dry cough, cough with blood due to fatigue, insufficient essence and blood, soreness of the waist and knees, premature graying of hair, internal heat and thirst.
[0003] Polygonatum contains multiple chemical components such as polysaccharides, saponins, triterpenes, alkaloids, lignans, flavonoids, phytosterols and volatile oils, among which polysaccharides and saponins are relatively large in amount and are the main effective ingredients. According to relevant literature reports, Polygonatum polysaccharide is one of the main biologically active ingredients of Polygonatum, with multiple biological activities such as enhancing immune function, anti-tumor, and anti-radiation. The neutral saponins contained in Polygonatum are steroidal saponins, and the saponin components mainly include diosgenin, digitonin and smilaxone. Modern pharmacological studies have shown that steroidal saponins have multiple pharmacological activities such as regulating blood sugar, preventing and treating cardiovascular and cerebrovascular diseases, anti-tumor, and improving learning and memory. In addition, flavonoids have functions such as anti-tumor, anti-virus, anti-aging, anti-bacterial and anti-inflammatory, anti-atherosclerosis, and protecting cardiovascular and cerebrovascular vessels. However, the research on extracts in Polygonatum plants in the prior art is not comprehensive. Summary of the invention
[0004] The purpose of the present invention is to overcome the problems existing in the prior art and to provide a flavonoid alkaloid extracted from Polygonatum cyrtonema and an extraction method and application thereof. The flavonoid alkaloid can inhibit the activity of α-glucosidase, has an antioxidant effect, and can be used to prepare drugs for treating or preventing diabetes and antioxidant drugs.
[0005] The first aspect of the present invention provides a flavonoid alkaloid extracted from Polygonatum cyrtonema, wherein the flavonoid alkaloid is selected from At least one of .
[0006] The second aspect of the present invention provides a method for extracting flavonoid alkaloids as described in the first aspect, comprising the following steps:
[0007] (1) mixing Polygonatum acanthopanax with an extraction solvent I to obtain an extract, and concentrating the extract to obtain a total extract;
[0008] (2) dispersing the total extract with water, extracting with petroleum ether, ethyl acetate and n-butanol, and concentrating to obtain a petroleum ether extract, an ethyl acetate extract and a n-butanol extract;
[0009] (3) The ethyl acetate extract is separated to obtain the flavonoid alkaloids.
[0010] Preferably, the extraction method further comprises: before the mixing in step (1), drying and crushing the Polygonatum cyrtonema.
[0011] Preferably, in step (1), the extraction solvent I is an ethanol-water solution.
[0012] Preferably, the volume ratio of ethanol to water in the extraction solvent I is 3-9:1.
[0013] Preferably, in step (1), the extraction method is percolation extraction.
[0014] Preferably, the percolation extraction is performed 3-6 times, and the conditions of each percolation extraction include: a temperature of 20-30° C. and a time of 3-4 days.
[0015] Preferably, in step (2), the weight ratio of the total extract to the water is 1:10-20.
[0016] Preferably, relative to 1 g of the total extract, the amount of petroleum ether is 1-3 g, the amount of ethyl acetate is 1-3 g, and the amount of n-butanol is 1-3 g.
[0017] Preferably, in step (3), the separation treatment comprises: S1, separating the ethyl acetate extract through a silica gel column I, and gradient eluting with a dichloromethane-methanol mixture to obtain eleven components Fr.A-Fr.K; S2, purifying the Fr.D component, the Fr.E component and the Fr.F component.
[0018] Preferably, in step S2, the purification comprises: separating the Fr.D component through a silica gel column II-1, and gradient eluting with a dichloromethane-methanol mixture to obtain ten components Fr.D.1-Fr.D.10; separating the Fr.D.10 component through a gel column II-2, isocratically eluting with methanol, and then continuing to separate it through a semi-preparative high performance liquid phase II-3, and gradient eluting with an acetonitrile-water mixture; separating the Fr.E component through a silica gel column III-1, and gradient eluting with a dichloromethane-methanol mixture to obtain eight components Fr.E.1-Fr.E.8; separating the Fr.E.5 component through a gel column III-2, and isocratically eluting with a dichloromethane-methanol mixture to obtain four components Fr.E.5.1-Fr.E.5.4; separating the Fr.E.5.1-Fr.E.5.4 The components were separated by semi-preparative high performance liquid phase separation III-3, and gradient eluted with a mixture of acetonitrile and water; the Fr.F component was separated by silica gel column IV-1, and gradient eluted with a mixture of dichloromethane and methanol to obtain seventeen components Fr.F.1-Fr.F.17; the Fr.F.2 component was separated by reverse phase column IV-2, and gradient eluted with a mixture of methanol and water to obtain sixteen components Fr.F.2.1-Fr.F.2.16; the Fr.F.2.14 component was separated by gel column IV-3, isocratically eluted with a mixture of dichloromethane and methanol, and then separated by semi-preparative high performance liquid phase separation IV-4, and gradient eluted with a mixture of acetonitrile and methanol. The Fr.F.2.10 component was separated by gel column IV-5, isocratically eluted with dichloromethane-methanol, and then separated by semi-preparative high performance liquid phase IV-6, and isocratically eluted with acetonitrile-water mixture; the Fr.F.17 component was separated by reverse phase column IV-7, and gradient eluted with methanol-water solution to obtain twenty components from Fr.F.17.1 to Fr.F.17.20; the Fr.F.17.14 component was separated by gel column IV-8, isocratically eluted with dichloromethane-methanol mixture, and then separated by semi-preparative high performance liquid phase IV-9, and isocratically eluted with acetonitrile-water mixture.
[0019] The third aspect of the present invention provides the use of the flavonoid alkaloids extracted from Polygonatum cyrtonema described in the first aspect and the flavonoid alkaloids extracted by the extraction method described in the second aspect in the preparation of drugs for treating or preventing diabetes and antioxidant drugs.
[0020] Through the above technical solution, the beneficial effects of the present invention are:
[0021] (1) The present invention extracts six new compounds from Polygonatum cyrtonema, and the compounds can inhibit the activity of α-glucosidase, have good antioxidant capacity, and can be used to prepare drugs for treating or preventing diabetes and antioxidant drugs.
[0022] (2) The compounds represented by Formula IV, Formula V, and Formula VI have a certain inhibitory effect on α-glucosidase activity, and the compounds represented by Formula II, Formula III, Formula IV, Formula V, and Formula VI have a strong scavenging ability for ABTS free radicals, and can be used to prepare drugs for treating or preventing diabetes and antioxidant drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 is the HR-ESI-MS spectrum of the compound represented by Formula I; Figure 2 is the 1H NMR spectrum of the compound represented by formula I; Figure 3 is the 13C NMR spectrum of the compound represented by Formula I; Figure 4 is the HSQC spectrum of the compound shown in Formula I; Figure 5 is the 1H-1H COSY spectrum of the compound represented by formula I; Figure 6 is the HMBC spectrum of the compound shown in Formula I; Figure 7 is a chiral chromatogram of the compound represented by formula I;
[0024] Figure 8 is the HR-ESI-MS spectrum of the compound represented by formula II; Fig. 9 is the 1H NMR spectrum of the compound represented by formula II; Fig.10 is the 13C NMR spectrum of the compound represented by formula II; Fig.11 is the HSQC spectrum of the compound represented by formula II; Fig.12 is the 1H-1H COSY spectrum of the compound represented by formula II; Fig.13 is the HMBC spectrum of the compound represented by formula II; Fig.14 is a chiral chromatogram of the compound represented by formula II;
[0025] Fig.15 is the HR-ESI-MS spectrum of the compound represented by formula III; Fig.16 is the 1H NMR spectrum of the compound represented by formula III; Fig.17 is the 13C NMR spectrum of the compound represented by formula III; Fig.18 is the HSQC spectrum of the compound represented by formula III; Fig.19 is the 1H-1H COSY spectrum of the compound represented by formula III; Fig. 20 is the HMBC spectrum of the compound represented by formula III; Fig.21 is a chiral chromatogram of the compound represented by formula III;
[0026] Fig. 22 is the HR-ESI-MS spectrum of the compound represented by Formula IV; Fig.23 is the 1H NMR spectrum of the compound represented by formula IV; Fig.24is the 13C NMR spectrum of the compound represented by formula IV; Fig.25 is the HSQC spectrum of the compound represented by formula IV; Fig.26 is the 1H-1H COSY spectrum of the compound represented by formula IV; Fig. 27 is the HMBC spectrum of the compound represented by formula IV; Fig.28 is a chiral chromatogram of the compound represented by formula IV;
[0027] Fig.29 is the HR-ESI-MS spectrum of the compound represented by Formula V; Fig.30 is the 1H NMR spectrum of the compound represented by formula V; Fig.31 is the 13C NMR spectrum of the compound represented by formula V; Fig.32 is the HSQC spectrum of the compound represented by Formula V; Fig.33 is the 1H-1H COSY spectrum of the compound represented by Formula V; Fig.34 is the HMBC spectrum of the compound represented by formula V; Fig.35 is a chiral chromatogram of the compound represented by formula V;
[0028] Fig.36 is the HR-ESI-MS spectrum of the compound represented by Formula VI; Fig.37 is the 1H NMR spectrum of the compound represented by Formula VI; Fig.38 is the 13C NMR spectrum of the compound represented by Formula VI; Fig.39 is the HSQC spectrum of the compound represented by Formula VI; Fig.40 is the 1H-1H COSY spectrum of the compound represented by Formula VI; Fig.41 is the HMBC spectrum of the compound represented by Formula VI; Fig.42 is a chiral chromatogram of the compound represented by Formula VI; Fig.43 It is the CD spectrum of the compound shown in formula VI. DETAILED DESCRIPTION
[0029] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0030] A first aspect of the present invention provides a flavonoid alkaloid extracted from Polygonatum sibiricum, wherein the flavonoid alkaloid is selected from at least one of the compounds shown in formula I, the compounds shown in formula II, the compounds shown in formula III, the compounds shown in formula IV, the compounds shown in formula V and the compounds shown in formula VI, wherein Formula I, Formula II, Formula III, Formula IV, Formula V and Formula VI are as shown above.
[0031] Specifically, the flavonoid alkaloid may be a compound shown in formula I, a compound shown in formula II, a compound shown in formula III, a compound shown in formula IV, a compound shown in formula V or a compound shown in formula VI, or may be a mixture of two of the compound shown in formula I, the compound shown in formula II, the compound shown in formula III, the compound shown in formula IV, the compound shown in formula V and the compound shown in formula VI, or may be a mixture of three of the compound shown in formula I, the compound shown in formula II, the compound shown in formula III, the compound shown in formula IV, the compound shown in formula V and the compound shown in formula VI, or may be a mixture of four of the compound shown in formula I, the compound shown in formula II, the compound shown in formula III, the compound shown in formula IV, the compound shown in formula V and the compound shown in formula VI, or may be a mixture of five of the compound shown in formula I, the compound shown in formula II, the compound shown in formula III, the compound shown in formula IV, the compound shown in formula V and the compound shown in formula VI, or may be a mixture of the compound shown in formula I, the compound shown in formula II, the compound shown in formula III, the compound shown in formula IV, the compound shown in formula V and the compound shown in formula VI.
[0032] The inventors of the present invention discovered during the research process that the compound shown in formula I, the compound shown in formula II, the compound shown in formula III, the compound shown in formula IV, the compound shown in formula V and the compound shown in formula VI can inhibit the activity of α-glucosidase, have antioxidant effects, and can be used to prepare drugs for treating or preventing diabetes and antioxidant drugs.
[0033] The second aspect of the present invention provides a method for extracting flavonoid alkaloids extracted from Polygonatum cyrtonema, comprising the following steps:
[0034] (1) mixing Polygonatum acanthopanax with an extraction solvent I to obtain an extract, and concentrating the extract to obtain a total extract;
[0035] (2) dispersing the total extract with water, extracting with petroleum ether, ethyl acetate and n-butanol, and concentrating to obtain a petroleum ether extract, an ethyl acetate extract and a n-butanol extract;
[0036] (3) separating and treating the ethyl acetate extract to obtain the flavonoid alkaloids;
[0037] The flavonoid alkaloid is selected from at least one of the compounds shown in formula I, the compounds shown in formula II, the compounds shown in formula III, the compounds shown in formula IV, the compounds shown in formula V and the compounds shown in formula VI.
[0038] According to the present invention, preferably, the extraction method further comprises: before the mixing in step (1), drying and crushing the Polygonatum sibiricum Red. In the present invention, Polygonatum sibiricum Red. refers to the rhizome of the plant of the genus Polygonatum of the family Liliaceae (Polygonatum sibiricum Red.), and its specific drying and crushing can adopt conventional drying and crushing methods in the art, for example, drying can be carried out by oven drying, sun drying or vacuum drying, and crushing can be carried out by a pulverizer, grinding, etc., and then the crushed Polygonatum sibiricum Red. can be sieved, and suitable Polygonatum sibiricum Red. particles can be selected for the next step.
[0039] According to the present invention, the extraction solvent I can be a lower fatty alcohol or an aqueous solution of a lower fatty alcohol, wherein the lower fatty alcohol can be methanol, ethanol, n-propanol, isopropanol, n-butanol, etc. In order to improve the effect of dissolution and extraction of flavonoid alkaloids from Polygonatum cyrtonema, preferably, the extraction solvent I in step (1) is an ethanol-water solution. Further preferably, the volume ratio of ethanol to water in the extraction solvent I is 3-9:1.
[0040] According to the present invention, the extraction method can adopt any feasible extraction method, such as high pressure extraction method, ultrasonic extraction method, etc. Preferably, in step (1), the extraction method is percolation extraction. This method can further improve the extraction efficiency of the active ingredient.
[0041] According to the present invention, there is no particular limitation on the number of times of percolation extraction of Polygonatum cyrtonema, the amount of extraction solvent used and the time, as long as the substances including flavonoid alkaloids can be effectively extracted. In order to further improve the extraction efficiency of the effective components, preferably, the number of percolation extractions is 3-6 times, and the conditions of each percolation extraction include: a temperature of 20-30° C. and a time of 3-4 days.
[0042] In the present invention, the concentration methods in step (1) and step (2) can be carried out by vacuum distillation or other conventional concentration methods.
[0043] According to the present invention, after extracting Polygonatum cyrtonema with extraction solvent I, the extract is obtained by solid-liquid separation, for example, by filtering or centrifuging.
[0044] According to the present invention, preferably, in step (2), the weight ratio of the total extract to the water is 1:10-20. The inventors found that under this preferred embodiment, the total extract has a better dispersion effect in water, which is convenient for the subsequent extraction of active ingredients and further improves the extraction efficiency.
[0045] In the present invention, the amount and time of using petroleum ether, ethyl acetate and n-butanol are not particularly limited, as long as the components containing flavonoid alkaloids can be separated and effectively extracted with ethyl acetate. Preferably, relative to 1g of total extract, the amount of petroleum ether is 1-3g, the amount of ethyl acetate is 1-3g, and the amount of n-butanol is 1-3g. In a specific embodiment of the present invention, relative to 1g of total extract, the amount of petroleum ether is 2g, the amount of ethyl acetate is 2g, and the amount of n-butanol is 2g.
[0046] According to the present invention, in order to further improve the separation effect, preferably, in step (3), the separation treatment includes: S1, separating the ethyl acetate extract through a silica gel column I, and gradient eluting with a dichloromethane-methanol mixed solution to obtain eleven components Fr.A-Fr.K; S2, purifying the Fr.D component, the Fr.E component and the Fr.F component.
[0047] According to the present invention, in order to further improve the separation effect, preferably, in step S2, the purification includes: separating the Fr.D component through a silica gel column II-1, and gradient eluting with a dichloromethane-methanol mixture to obtain ten components Fr.D.1-Fr.D.10; separating the Fr.D.10 component through a gel column II-2, isocratically eluting with methanol, and then continuing to separate it through a semi-preparative high-performance liquid phase II-3, and gradient eluting with an acetonitrile-water mixture; separating the Fr.E component through a silica gel column III-1, and The eight components Fr.E.1-Fr.E.8 were obtained by gradient elution with a dichloromethane-methanol mixture; the Fr.E.5 component was separated by a gel column III-2, and isocratically eluted with a dichloromethane-methanol mixture to obtain four components Fr.E.5.1-Fr.E.5.4; the Fr.E.5.4 component was separated by semi-preparative high performance liquid phase III-3, and gradient eluted with an acetonitrile-water mixture; the Fr.F component was separated by a silica gel column IV-1, and gradient eluted with a dichloromethane-methanol mixture to obtain Fr.F.1-Fr.F.17 are seventeen components; the Fr.F.2 component is separated by reverse phase column IV-2, and gradient eluted with methanol-water mixture to obtain sixteen components Fr.F.2.1-Fr.F.2.16; the Fr.F.2.14 component is separated by gel column IV-3, isocratically eluted with dichloromethane-methanol mixture, and then separated by semi-preparative high performance liquid phase IV-4, and isocratically eluted with acetonitrile-water mixture; the Fr.F.2.10 component is separated by gel column IV-5, and isocratically eluted with acetonitrile-water mixture. After isocratic elution with dichloromethane-methanol, the mixture was separated by semi-preparative high performance liquid phase separation IV-6, and isocratic elution was performed with an acetonitrile-water mixture; the Fr.F.17 component was separated by reverse phase column IV-7, and gradient eluted with a methanol-water solution to obtain twenty components, Fr.F.17.1-Fr.F.17.20; the Fr.F.17.14 component was separated by gel column IV-8, and isocratic elution was performed with a dichloromethane-methanol mixture, and then separated by semi-preparative high performance liquid phase separation IV-9, and isocratic elution was performed with an acetonitrile-water mixture.
[0048] In the present invention, silica gel column separation is a column chromatography silica gel separation method disclosed in the prior art. The silica gel column can be selected from conventional column chromatography silica gel in the art, which can be purchased commercially or prepared by itself. For example, the column chromatography silica gel with specifications of 80-100 mesh, 100-200 mesh, 200-300 mesh, and 300-400 mesh produced by Qingdao Ocean Chemical Plant is used. In silica gel column separation I, silica gel column separation II-1, silica gel column separation III-1, and silica gel column separation IV-1, a dichloromethane-ethanol mixed solution is used for gradient elution, and the volume ratio of dichloromethane to methanol is 1:0 to 0:1.
[0049] In the present invention, gel column separation is a column chromatography gel separation method disclosed in the prior art, and the gel column can be selected from a Sephadex LH-20 gel column with a specification of 500g produced by GE Healthcare Co., Ltd. of the United States. In gel column separation III-2, gel column separation IV-3, gel column separation IV-5, and gel column separation IV-8, isocratic elution is performed with a dichloromethane-methanol mixture, and the volume ratio of dichloromethane to methanol can be any value, and the effective components containing flavonoid alkaloids can be extracted. For example, in gel column separation III-2, gel column separation IV-3, gel column separation IV-5, and gel column separation IV-8, the volume ratio of dichloromethane to methanol is 0:1, 1:1 or 3:7.
[0050] In the present invention, the reversed-phase column separation adopts the conventional reversed-phase column separation method in the art, and the reversed-phase column uses conventional silica gel fillers in the art, which can be purchased commercially or prepared by itself. In reversed-phase column separation IV-2 and reversed-phase column separation IV-7, a methanol-water mixture is used for gradient elution, and the volume ratio of methanol to water can be any value, as long as the effective ingredients containing flavonoid alkaloids can be extracted. Exemplarily, in reversed-phase column separation IV-2 and reversed-phase column separation IV-7, the volume ratio of methanol to water is 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, 100:0.
[0051] In the present invention, semi-preparative high-performance liquid phase separation can be carried out using conventional methods and instruments in the art. In semi-preparative high-performance liquid phase separation II-3 and semi-preparative high-performance liquid phase separation III-3, gradient elution is performed with an acetonitrile-water mixture, and the volume ratio of acetonitrile to water can be any value, as long as the effective components containing flavonoid alkaloids can be extracted. Exemplarily, in semi-preparative high-performance liquid phase separation II-3 and semi-preparative high-performance liquid phase separation III-3, the volume ratio of acetonitrile to water is 20:80 to 70:30. In semi-preparative high-performance liquid phase separation IV-4, semi-preparative high-performance liquid phase separation IV-6, and semi-preparative high-performance liquid phase separation IV-9, isocratic separation is performed with a methanol-water mixture. For example, in semi-preparative high-performance liquid phase separation IV-4 and semi-preparative high-performance liquid phase separation IV-6, the volume ratio of methanol to water is 32:68, 35:65 or 30:70.
[0052] The third aspect of the present invention provides the use of the flavonoid alkaloids extracted from Polygonatum cyrtonema described in the first aspect and the flavonoid alkaloids extracted by the extraction method described in the second aspect in the preparation of drugs for treating or preventing diabetes and antioxidant drugs.
[0053] In the present invention, the flavonoid alkaloids extracted from Polygonatum cyrtonema can be used directly or in the form of a pharmaceutical composition when used to prepare a drug for treating or preventing diabetes and an antioxidant drug. The drug for treating or preventing diabetes and the antioxidant drug can contain 0.1-99.9% by weight of the flavonoid alkaloids, and the rest is a pharmaceutical carrier or excipient, which can be one or more solid, semi-solid and liquid diluents, fillers and pharmaceutical product adjuvants.
[0054] In the present invention, the dosage forms of the drug for treating or preventing diabetes and the antioxidant drug include injection, suspension, emulsion, solution, syrup, tablet, capsule, granule, granule, spray and aerosol.
[0055] According to a particularly preferred embodiment of the present invention, a method for extracting flavonoid alkaloids extracted from Polygonatum cyrtonema is provided, comprising the following steps:
[0056] (1) drying and crushing the Polygonatum cyrtonema, and then mixing it with an ethanol-water solution (the volume ratio of ethanol to water is 3-9:1) at a weight ratio of 1:1.5-3 for extraction, and obtaining an extract after solid-liquid separation, and concentrating the extract to obtain a total extract;
[0057] (2) dispersing the total extract with water (the weight ratio of the total extract to water is 1:10-20), extracting with petroleum ether, ethyl acetate and n-butanol in sequence, and concentrating to obtain petroleum ether extract, ethyl acetate extract and n-butanol extract, wherein, relative to 1 g of the total extract, the amount of petroleum ether is 1-3 g, the amount of ethyl acetate is 1-3 g, and the amount of n-butanol is 1-3 g;
[0058] (3) Separating the ethyl acetate extract through a silica gel column, and gradient eluting with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol is 1:0 to 0:1), using 10% concentrated sulfuric acid vanillin as a color developer, and performing TLC thin layer analysis to obtain eleven components, Fr.A-Fr.K;
[0059] The Fr.D component was separated by silica gel column II-1, and gradient eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol is 1:0 to 0:1) to obtain ten components Fr.D.1-Fr.D.10; the Fr.D.10 component was separated by gel column II-2, isocratically eluted with methanol, and then continued to be separated by semi-preparative high performance liquid phase II-3, and gradient eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile to water is 20:80 to 70:30, respectively), to obtain the compound of formula I;
[0060] The Fr.E component was separated by silica gel column III-1, and gradient eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 1:0 to 0:1) to obtain eight components Fr.E.1-Fr.E.8; the Fr.E.5 component was separated by gel column III-2, and isocratically eluted with a dichloromethane-methanol mixture (the volume ratio was 1:1) to obtain four components Fr.E.5.1-Fr.E.5.4; the Fr.E.5.4 component was separated by semi-preparative high performance liquid phase III-3, and gradient eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile to water was 20:80 to 70:30, respectively), to obtain the compound represented by formula V;
[0061] The Fr.F component was separated into IV-1 by silica gel column, and gradient eluted with dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 1:0 to 0:1) to obtain 17 components Fr.F.1-Fr.F.17; the Fr.F.2 component was separated into IV-2 by reverse phase column, and gradient eluted with methanol-water mixture (the volume ratio of methanol to water was 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, 100:0) gradient elution to obtain sixteen components Fr.F.2.1-Fr.F.2.16; Fr.F.2.14 component was separated by gel column IV-3, isocratically eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 1:1), and then separated by semi-preparative high-performance liquid phase IV-4, and isocratically eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile to water was 35:65) to obtain the compound of formula VI; Fr.F.2.10 The component IV-5 was separated by gel column, and after isocratic elution with dichloromethane-methanol (the volume ratio of dichloromethane to water is 1:1), it was further separated by semi-preparative high performance liquid phase IV-6, and isocratic elution with acetonitrile-water mixture (the volume ratio of acetonitrile to water is 30:70) to obtain the compound of formula II; the Fr.F.17 component was separated by reverse phase column IV-7, and eluted with methanol-water solution (the volume ratio of methanol to water is 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, 100:0) gradient elution to obtain 20 components Fr.F.17.1-Fr.F.17.20; the Fr.F.17.14 component was separated by gel column IV-8, isocratically eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane and methanol is 3:7), and then continued to be separated by semi-preparative high-performance liquid phase IV-9, and isocratically eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile and water is 32:68) to obtain the compound of formula III and the compound of formula IV.
[0062] The compound extracted by the above extraction method can inhibit the activity of α-glucosidase, has an antioxidant effect, and can be used to prepare drugs for treating or preventing diabetes and antioxidant drugs.
[0063] The present invention will be described in detail below through examples.
[0064] In the following examples, the medicinal material Polygonatum sibiricum was purchased in Mei County, Baoji City, Shaanxi Province in January 2020, and was identified as the rhizome of Polygonatum sibiricum Red. of the genus Polygonatum of the Liliaceae by Professor Wang Wei of the International Joint Laboratory of Traditional Chinese Medicine and Ethnic Medicine of Hunan University of Chinese Medicine. The medicinal material specimen (No. 20200112) is currently stored in the International Joint Laboratory of Traditional Chinese Medicine and Ethnic Medicine of Hunan University of Chinese Medicine.
[0065] The darkbox UV analyzer was purchased from Hangzhou Qiwei Instrument Co., Ltd. with the instrument model of WFH-203B. The Fourier transform infrared spectrometer was purchased from PerkinElmer Co., Ltd., USA with the instrument model of Frontier MIR. The UV-visible spectrophotometer was purchased from PerkinElmer Co., Ltd., USA with the instrument model of Lambda650. The polarimeter was purchased from Rudolph Corporation, USA with the instrument model of AUTOPOL Ⅲ. The semi-preparative high performance liquid chromatograph was purchased from Agilent Technologies Co., Ltd., USA with the instrument model of Agilent 1260. The analytical high performance liquid chromatograph was purchased from Agilent Technologies Co., Ltd., USA with the instrument model of Agilent 1260. The nuclear magnetic resonance instrument was purchased from Bruker Technology Co., Ltd., Germany with the instrument model of AV-600. The mass spectrometer was purchased from Waters Corporation, USA with the instrument model of Xevo G2-S QTOF. The circular dichroism spectrometer was purchased from Biologic Company, France with the instrument model of MOS-500.
[0066] Petroleum ether, ethyl acetate and dichloromethane were purchased from Shanghai Titan Technology Co., Ltd.; chloroform was purchased from Hunan Huihong Reagent Co., Ltd.; methanol and acetonitrile were purchased from Merck Life Science Technology Co., Ltd.; cyclohexane and anhydrous methanol were purchased from Sinopharm Chemical Reagent Co., Ltd.; deuterated methanol was purchased from Cambridge Isotope Laboratory, USA; thin layer chromatography silica gel plates were purchased from Yantai Jiangyou Silica Gel Development Co., Ltd., with specifications of GF 254 (5×10 cm); column chromatography silica gel was purchased from Qingdao Ocean Chemical Co., Ltd., with specifications of 80-100 mesh / 200-300 mesh; Sephadex LH-20 gel was purchased from GE Healthcare Co., Ltd., USA, with specifications of 500 g; concentrated sulfuric acid-vanillin color developer was prepared by this laboratory, with specifications of 10% sulfuric acid-vanillin. Unless otherwise specified, other reagents and raw materials are conventional commercial products.
[0067] In the following examples, unless otherwise specified, the room temperature is 25±5°C.
[0068] Example 1
[0069] (1) Take 37 kg of dried Polygonatum cyrtonema, grind it, and use 75 L of ethanol-water solution with an ethanol concentration of 90% by volume to extract it three times, each time for 3 days, recover the extract, and concentrate it under reduced pressure to obtain a 90% ethanol extract of Polygonatum cyrtonema. After extraction with 90% ethanol, use an alcohol meter to make the recovered 90% ethanol into 75% ethanol, and continue to extract by percolation, each time for 3 days, with continuous stirring during the process. After the extraction is completed, the extract is concentrated under reduced pressure to obtain a 75% ethanol extract of Polygonatum cyrtonema. Combine the 90% ethanol extract and the 75% ethanol extract, dry them, and obtain 10 kg of total extract;
[0070] (2) 10 kg of the total extract was dispersed in 15 L of water and extracted in two batches, and extracted three times with 2 times the amount of petroleum ether, ethyl acetate and n-butanol in sequence, and the three organic phases were combined and concentrated under reduced pressure to obtain 183 g of petroleum ether extract, 85 g of ethyl acetate extract and 800 g of n-butanol extract;
[0071] (3) 85 g of the ethyl acetate extract was subjected to silica gel column chromatography, gradient eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 1:0, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 8:1, 5:1, 2:1, 1:1, 0:1), and analyzed by TLC. Other fractions with similar color and polarity were combined to obtain eleven components, namely, Fr.A-Fr.K;
[0072] 10.5 g of Fr.D component was subjected to 300-400 mesh silica gel column chromatography and gradient eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 1:0, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 8:1, 5:1, 2:1, 1:1, 0:1) to obtain ten components Fr.D.1-Fr.D.10; 527.9 mg of Fr.D.10 component was subjected to Sephadex-LH20 column chromatography and isocratically eluted with 100% methanol, and then subjected to semi-preparative high performance liquid chromatography and eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile to water was 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30) gradient elution to obtain 5.0 mg of the compound of formula I;
[0073] 7.5 g of Fr.E component was subjected to 300-400 mesh silica gel column chromatography and gradient eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 1:0, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 8:1, 5:1, 2:1, 1:1, 0:1) to obtain eight components Fr.E.1-E.8; 7.5 g of Fr.E.5 component was subjected to Sephadex-LH20 column chromatography and isocratically eluted with a dichloromethane-methanol mixture (volume ratio was 1:1) to obtain four components Fr.E.5.1-E.5.4; 22.5 mg The Fr.E.5.4 component was subjected to semi-preparative HPLC and gradient eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile to water was 20:80, 25:75, 30:70, 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30) to obtain 2.0 mg of the compound represented by formula V;
[0074] 14.3 g of Fr.F component was subjected to 300-400 mesh silica gel column chromatography and gradient eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 1:0, 100:1, 90:1, 80:1, 70:1, 60:1, 50:1, 40:1, 30:1, 20:1, 10:1, 8:1, 5:1, 2:1, 1:1, 0:1) to obtain 17 components Fr.F.1-F.17; 1.2 g of Fr.F.2 component was subjected to reverse phase ODS column chromatography and gradient eluted with a methanol-water mixture (the volume ratio of methanol to water was 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, 100:0) Gradient elution was performed to obtain sixteen components, namely, Fr.F.2.1-F.2.16; 85.8 mg of the Fr.F.2.14 component was subjected to Sephadex-LH20 column chromatography, isocratically eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 1:1), and then subjected to semi-preparative high performance liquid chromatography, and isocratically eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile to water was 35:65), to obtain 3.8 mg of the compound represented by formula VI; 35.0 mg of the Fr.F.2.10 component was subjected to Sephadex-LH20 column chromatography, isocratically eluted with dichloromethane-methanol (the volume ratio of dichloromethane to water was 1:1), and then subjected to semi-preparative high performance liquid chromatography, and isocratically eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile to water was 30:70), to obtain 2.4 mg of the compound represented by formula II; 1.8 g The Fr.F.17 component was subjected to reverse phase ODS column chromatography and gradient eluted with methanol-water solution (the volume ratio of methanol to water was 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 70:30, 80:20, 90:10, 100:0) to obtain 20 components Fr.F.17.1-F.17.20; 13.7 mg of the Fr.F.17.14 component was subjected to Sephadex-LH20 column chromatography and isocratically eluted with a dichloromethane-methanol mixture (the volume ratio of dichloromethane to methanol was 3:7), and then subjected to semi-preparative high performance liquid chromatography and isocratically eluted with an acetonitrile-water mixture (the volume ratio of acetonitrile to water was 32:68) to obtain 2.0 mg of the compound represented by formula III and 3.2 mg of the compound represented by formula IV.
[0075] Test Example 1
[0076] Characterization of the compound shown in Formula I:
[0077] The compound is a white amorphous powder (DMSO), reddish brown by vanillin-concentrated sulfuric acid reaction (TLC), and positive by FeCl3 color development, indicating the presence of phenolic hydroxyl groups; UV spectrum has maximum absorption at 290nm, 224nm and 205nm; IR spectrum shows hydroxyl groups (3374cm -1 ), carbonyl (1674cm -1 and 1639cm -1 ) and benzene ring (1500cm -1 and 1452cm -1 ) characteristic absorption; HR-ESI-MS analysis results are shown in Figure 1 HR-ESI-MS spectrum shows quasi-molecular ion peak m / z 386.1242[M+H] + (calcdfor C 20 H 20 NO7: 386.1240), the molecular formula of the compound can be determined to be C 20 H 19 NO7.
[0078] like Figure 2 As shown, the compound 1 The H NMR spectrum (600 MHz, DMSO-d6) showed two groups of very similar proton signals, some of which overlapped. Including the four pairs of phenolic hydroxyl hydrogen signals [δ H 12.22 (1H, s, 5-OH) and 12.21 (1H, s, 5-OH), 10.76 (1H, s, 7-OH) and 10.75 (1H, s, 7-OH), 9.29 (1H, s, 4'-OH) and 9.28 (1H, s, 4'-OH), 9.27 (2H, s, 2'-OH)], 4 pairs of benzene ring hydrogen signals [δ H 6.80 (1H, s, H-6') and 6.76 (1H, s, H-6'), 6.38 (2H, s, H-3'), 5.87 (2H, d, J=2.1Hz, H-6), 5.86 (1H, m, H-8) and 5.85 (1H, d, J=1.9Hz, H-8)].
[0079] It is worth noting that Figure 3 As shown, the compound 13 The carbon rod of the C NMR spectrum (150MHz, DMSO-d6) splits, showing two groups of carbon signals with very similar chemical shifts. Therefore, during the analysis process, the chemical shift of carbon will be retained to two decimal places. Each group has 20 carbon signals. Combined with the DEPT 135° spectrum, it is suggested that there are two pairs of carbonyl carbon signals [δ C198.19 (C-4) and 198.17 (C-4), 177.08 (C-2") and 177.06 (C-2")], two groups of carbon signals of benzene rings [δ C 166.46 (C-7) and 166.43 (C-7), 163.78 (C-5), 162.83 (C-8a) and 162.81 (C-8a), 154.84 (C-2') and 154.78 (C-2'), 153.57 (C-4'), 127.84 (C-6') and 127.75 (C-6'), 120.02 (C-5') and 119.98 (C-5'), 114.47 (C-1') and 114.27 (C-1'), 102.39 (C-3') and 102.38 (C-3'), 101.28 (C-4a) and 101.24 (C-4a), 95.84 (C-6) and 95.82 (C-6), 94.66 (C-8) and 94.63 (C-8). In addition, there are 4 pairs of methylene carbon signals [δ C 69.07 (C-2) and 68.98 (C-2), 30.10 (C-3") and 30.06 (C-3"), 29.40 (C-4") and 29.39 (C-4"), 26.65 (C-9) and 26.38 (C-9)].
[0080] according to 1 H NMR, 13 C NMR, 1 H- 1 For information on H COSY, HSQC, and HMBC spectra, see Figure 2-Figure 6 .exist 1 H- 1 In the H COSY spectrum, two groups of proton coupling systems can be observed, namely: δ H 4.25(H-2a), 2.43 (H-9b) and
[0081] In the HMBC spectrum, δ H 4.25(H-2a), 4.15(H-2b) and δ C 198.19(C-4) / 162.81(C-8a), δ H 3.02(H-9a), 2.43(H-9b) and δ C 69.07(C-2) / 127.84(C-6') / 154.78(C-2') have long-range correlation, forming a high isoflavone skeleton. Excluding the data of the high isoflavone fragment, δ H 4.76(H-5") and δ C127.84(C-6') / 153.57(C-4') / 177.08(C-2") are remotely related, forming a five-membered ring connected to the C-5' position and containing a carbonyl group. From the chemical shift of C-5", it is speculated that it is connected to N.
[0082] In summary, it can be determined that the planar structure of the compound is a high isoflavone alkaloid with a five-membered lactam ring connected to the C-5' position of the B ring, and its planar structure is as follows:
[0083]
[0084] When determining its absolute configuration, the compound's optical rotation value is close to 0, and there is no obvious cotton effect. Since the compound contains two chiral centers in its molecular structure, it is speculated that it may be a mixture of two groups of enantiomeric racemates. OJ30CE-WA008 was used for chiral analysis. The chromatographic conditions were [mobile phase: n-hexane / ethanol / diethylamine = 60 / 40 / 0.1 (v / v / v), flow rate: 0.8mL / min, injection volume: 10μL, detection wavelength: 210nm, column temperature: 35℃], and three chromatographic peaks with a peak area ratio of about 1:2:1 appeared. The three chromatographic peaks were scanned at full wavelength, and their ultraviolet absorption was completely consistent. Therefore, the compound was determined to be two groups of enantiomeric racemates Ia and Ib. The chiral analysis chromatogram is shown in Figure 7 .
[0085] The structural formula of the compound is:
[0086] Test Example 2
[0087] Characterization of the compound shown in formula II:
[0088] The compound is a white amorphous powder (CH3OH). The vanillin-concentrated sulfuric acid reaction (TLC) is reddish brown, indicating that the compound contains flavonoid structural fragments. The FeCl3 color development reaction is positive, indicating that it contains phenolic hydroxyl groups. The UV spectrum has maximum absorption at 290nm, 224nm and 203nm. The IR spectrum shows that the hydroxyl group (3238cm -1 ), carbonyl (1634cm -1 and 1603cm -1 ) and benzene ring (1501cm -1 and 1454cm -1 ) characteristic absorption; HR-ESI-MS analysis results are shown in Figure 8 HR-ESI-MS spectrum showed quasi-molecular ion peak m / z 386.1232[M+H] +(calcd for C 20 H 20 NO7: 386.1240), the molecular formula of the compound can be determined to be C 20 H 19 NO7.
[0089] like Fig. 9 As shown, the compound 1 The H NMR spectrum (600MHz, CD3OD) shows two sets of proton signals with high overlap, one of which will be used for analysis. This compound includes four benzene ring hydrogen signals [δ H 6.85 (1H, d, J = 8.3 Hz, H-6') and 6.34 (1H, d, J = 8.2 Hz, H-5'), 5.87 (1H, d, J = 2.2 Hz, H-6) and 5.84 (1H, d, J = 2.1 Hz, H-8)].
[0090] like Fig.10 As shown, the compound 13 In the C NMR spectrum (150MHz, CD3OD), most carbon signals appear in pairs, and one of the data sets will be selected as the basis for the analysis process. Combined with the DEPT 135° spectrum, it is suggested that there are two pairs of carbonyl carbon signals [δ C 200.2 (C-4) and 181.9 (C-2")], the carbon signals of the two benzene rings [δ C 168.4 (C-7), 165.7 (C-5), 164.9 (C-8a), 157.1 (C-4'), 155.2 (C-2'), 131.5 (C-6'), 118.0 (C-1'), 117.6 (C-3'), 108.9 (C-5'), 102.9 (C-4a), 97.0 (C-6) and 95.8 (C-8). In addition, there are 4 pairs of methylene carbon signals [δ C 70.7 (C-2), 32.3 (C-3"), 27.0 (C-4") and 27.9 (C-9)].
[0091] according to 1 H NMR, 13 C NMR, 1 H- 1 For information on H COSY, HSQC, and HMBC spectra, see Figure 9-13 .exist 1 H- 1 In the H COSY spectrum, three groups of proton coupling systems can be observed, namely: δ H 4.31(H-2a), 2.68(H-9b), and 2.41(H-3"b).
[0092] In the HMBC spectrum, δ H 4.31(H-2a), 4.10(H-2b) and δ C 200.2(C-4) / 164.9(C-8a),δ H 3.11(H-9a), 2.68(H-9b) and δ C 70.7(C-2) / 131.5(C-6') / 155.2(C-2') have long-range correlation, forming a high isoflavone skeleton. Excluding the data of the high isoflavone fragment, δ H 4.76(H-5") and δ C There is a long-range correlation at 155.2 (C-2') / 157.1 (C-4') / 181.9 (C-2"), and combined with the proton coupling system, it is speculated that there is a five-membered ring containing a carbonyl group at the C-3' position. From the chemical shift of C-5", it is speculated that it is connected to N.
[0093] In summary, it can be determined that the planar structure of compound II is a high isoflavone alkaloid with a five-membered lactam ring connected to the C-3' position of the B ring, and its planar structure is as follows:
[0094]
[0095] When determining the absolute configuration of the compound, it was found to be similar to the compound shown in Formula I. AD30CE-WE006 performed chiral analysis on it, and the chromatographic conditions [mobile phase: n-hexane / isopropanol=85 / 15 (v / v), flow rate: 1.0mL / min, injection volume: 5μL, detection wavelength: 210nm, column temperature: 35℃], showing 4 chromatographic peaks with a peak area ratio of 1:1:1:1. After full wavelength scanning, the ultraviolet absorption of the 4 chromatographic peaks is exactly the same, proving that the 4 chromatographic peaks are the same type of compound. It can be seen that the compound is a racemic isomer of two pairs of enantiomers, namely IIa, IIb, IIc and IId. The chiral analysis chromatogram is shown in Fig.14 Chiral analysis showed that the two chiral centers C-3 and C-5" in the molecular structure of the compound can exist in R or S configuration at the same time, producing four isomers: (3R, 5"S), (3R, 5"R), (3S, 5"R) and (3S, 5"S).
[0096] The structural formula of the compound is:
[0097] Test Example 3
[0098] Characterization of the compound shown in formula III:
[0099] The compound is a white amorphous powder (CH3OH). The vanillin-concentrated sulfuric acid reaction (TLC) is reddish brown, indicating that the compound contains flavonoid structural fragments; the FeCl3 color development reaction is positive, indicating that it contains phenolic hydroxyl groups; the UV spectrum has maximum absorption at 290nm and 224nm; the IR spectrum shows that the hydroxyl group (3348cm -1 ), carbonyl (1618cm -1 ) and benzene ring (1519cm -1 and 1449cm -1 ) characteristic absorption; HR-ESI-MS analysis results are shown in Fig.15 HR-ESI-MS spectrum shows quasi-molecular ion peak m / z384.1076[MH] + (calcd for C 20 H 18 NO7: 384.1083), the molecular formula of the compound can be determined to be C 20 H 19 NO7.
[0100] like Fig.16 As shown, the compound 1 The H NMR spectrum (600MHz, CD3OD) shows two sets of proton signals with high overlap, and one of them will be used as the basis for the analysis process. This compound has four benzene ring hydrogen signals [δ H 6.86 (1H, d, J = 8.1 Hz, H-6'), 6.30 (1H, d, J = 1.9 Hz, H-3'), 6.23 (1H, dd, J = 8.1, 2.4 Hz, H-5') and 5.90 (1H, s, H-8)].
[0101] like Fig.17 As shown, the compound 13 In the C NMR spectrum (150MHz, CD3OD), most carbon signals appear in pairs, and one of the data sets will be selected as the basis for the analysis process. Combined with the DEPT 135° spectrum, it is suggested that there are two pairs of carbonyl carbon signals [δ C 200.6 (C-4) and 181.6 (C-2")], the carbon signals of the two benzene rings [δ C166.1 (C-7), 163.9 (C-8a), 163.7 (C-5), 158.4 (C-4'), 157.6 (C-2'), 132.6 (C-6'), 116.7 (C-1'), 109.2 (C-6), 107.4 (C-5'), 103.5 (C-3'), 102.6 (C-4a) and 95.4 (C-8). In addition, there are 4 pairs of methylene carbon signals [δ C 70.6 (C-2), 32.0 (C-3"), 26.6 (C-4") and 28.2 (C-9)].
[0102] according to 1 H NMR, 13 C NMR, 1 H- 1 For information on H COSY, HSQC, and HMBC spectra, see Figure 16-Figure 20 .exist 1 H- 1 In the H COSY spectrum, three groups of proton coupling systems can be observed, namely: δ H 4.24(H-2a), 2.56(H-9b), and 2.38 (H-3"b).
[0103] In the HMBC spectrum, δ H 4.24 (H-2a), 4.10 (H-2b) and δ C 200.6(C-4) / 163.9(C-8a),δ H 3.14 (H-9a), 2.56 (H-9b) and δ C 70.6(C-2) / 132.6(C-6') / 157.6(C-2') have long-range correlation, forming a high isoflavone skeleton. Excluding the data of the high isoflavone fragment, δ H 5.34(H-5") and δ C There is a long-range correlation between 166.1(C-7) / 163.7(C-5) / 181.6(C-2”), and combined with the proton coupling system, it is speculated that there is a five-membered ring containing a carbonyl group at the C-6 position. From the chemical shift of C-5”, it is speculated that it is connected to N.
[0104] In summary, it can be determined that the planar structure of the compound is a high isoflavone alkaloid with a five-membered lactam ring connected to the C-6 position of the A ring, and its planar structure is as follows:
[0105]
[0106] The planar structure of the compound is similar to that of the compound shown in Formula I and the compound shown in Formula II, except for the substitution position of the lactam ring. When determining its stereo configuration, it was found that its optical rotation value was close to 0, with no obvious cotton effect, and from the fact that the hydrogen spectrum and carbon spectrum NMR data of the compound appeared in pairs, it was speculated that it also existed in the form of two pairs of enantiomeric racemates. Chiral analysis of AYH0CE-VB023 (chromatographic conditions: mobile phase: n-hexane / ethanol=80 / 20 (v / v), flow rate: 1.0 mL / min, injection volume: 5 μL, detection wavelength: 210 nm, column temperature: 35°C), the compound showed 4 chromatographic peaks with a peak area ratio of about 1:1:1:1. Full wavelength scanning found that the ultraviolet absorption of the 4 chromatographic peaks was consistent, proving that the compound was a racemic isomer of 2 pairs of enantiomers, namely IIIa, IIIb, IIIc and IIId. The chiral analysis chromatogram is shown in Fig.21 Chiral analysis proved that the lactam ring in the molecular structure of the compound connected to the III of the homoisoflavone A ring also exists simultaneously in four isomers: (3R, 5"S), (3R, 5"R), (3S, 5"R) and (3S, 5"S).
[0107] The structural formula of the compound is:
[0108] Test Example 4
[0109] Characterization of the compound shown in formula IV:
[0110] The compound is a white amorphous powder (CH3OH). The vanillin-concentrated sulfuric acid reaction (TLC) is reddish brown, indicating that the compound contains flavonoid structural fragments; the FeCl3 color development reaction is positive, indicating that it contains phenolic hydroxyl groups; the UV spectrum has maximum absorption at 292nm and 224nm; the IR spectrum shows that the hydroxyl group (3387cm -1 ), carbonyl (1637cm -1 ), benzene ring (1500cm -1 and 1436cm -1 ) and methyl (1379cm -1 ) characteristic absorption; HR-ESI-MS analysis results are shown in Fig. 22 HR-ESI-MS spectrum shows quasi-molecular ion peak m / z 398.1227[MH] + (calcd for C 21 H 20 NO7: 398.1240), the molecular formula of the compound can be determined to be C 20 H 21 NO7.
[0111] like Fig.23 As shown, the compound 1 The H NMR spectrum (600 MHz, CD3OD) showed two groups of hydrogen signals with very close or even overlapping chemical shifts, so one of them was used as the basis for structural analysis in determining the planar configuration of the compound. The hydrogen spectrum showed three benzene ring hydrogen signals [δ H 6.84 (1H, s, H-6'), 6.35 (1H, s, H-3') and 5.91 (1H, s, H-6)] and one methyl signal [δ H 1.91 (3H, s, 8-CH3)].
[0112] like Fig.24 As shown, the compound 13 In the C NMR spectrum (150MHz, CD3OD), most carbon signals appear in pairs, and one of the data sets will be selected as the basis for the analysis process. Combined with the DEPT 135° spectrum, it is suggested that there are two pairs of carbonyl carbon signals [δ C 200.5 (C-4) and 181.4 (C-2")], the carbon signals of the two benzene rings [δ C 166.0 (C-7), 163.2 (C-5), 161.6 (C-8a), 156.8 (C-2'), 155.5 (C-4'), 129.6 (C-6'), 120.8 (C-5'), 116.6 (C-1'), 104.2 (C-8), 103.6 (C-3'), 102.8 (C-4a) and 96.1 (C-6). In addition, there are 4 pairs of methylene carbon signals [δ C 70.6 (C-2), 31.4 (C-3”), 30.0 (C-4”) and 28.2 (C-9)] and one methyl carbon signal [δ C 7.4(8-CH3)].
[0113] according to 1 H NMR, 13 C NMR, 1 H- 1 For information on H COSY, HSQC, and HMBC spectra, see Figure 23-Figure 27 .exist 1 H- 1 In the H COSY spectrum, two groups of proton coupling systems can be observed, namely: δ H 4.29(H-2a), 2.60 (H-9b) and 2.36 (H-3"b).
[0114] In the HMBC spectrum, δ H4.29 (H-2a), 4.15 (H-2b) and δ C 200.5(C-4) / 161.6(C-8a),δ H 3.15(H-9a), 2.60(H-9b) and δ C 70.6(C-2) / 129.6(C-6') / 156.8(C-2') have long-range correlation, forming a high isoflavone skeleton. Excluding the data of the high isoflavone fragment, δ H 4.96(H-5") and δ C 129.6 (C-6') / 155.5 (C-4') / 181.4 (C-2") have long-range correlations, suggesting that a five-membered ring containing a carbonyl group is attached to the C-5' position of the B ring. From the chemical shift of C-5", it is speculated that it is attached to N. In addition, δ H 1.91(CH3) and δ C 166.0(C-7) / 161.6(C-8a) have long-range correlation, so the methyl group is attached to the 8-carbon atom of the A ring.
[0115] In summary, it can be determined that the planar structure of the compound is a high isoflavone alkaloid with a five-membered lactam ring connected to the C-5' position of the B ring and a 5-membered lactam ring connected to the 8th position of the A ring. Its planar structure is as follows:
[0116]
[0117] Compared with the compound shown in Formula I, this compound has an additional methyl group at C-8, and its optical rotation value is close to 0, without obvious cotton effect. Chiral analysis was performed on it by ADH0CD-XC030 (chromatographic conditions: mobile phase: n-hexane / ethanol=75 / 25 (v / v), flow rate: 1.0 mL / min, injection volume: 5 μL, detection wavelength: 210 nm, column temperature: 35° C.), and it was found that it was 2 pairs of enantiomeric racemates, namely IVa, IVb, IVc and IVd. The chiral analysis chromatogram is shown in Fig.28 .
[0118] The structural formula of the compound is:
[0119] Test Example 5
[0120] Characterization of the compound shown in Formula V:
[0121] The compound is a white powder (CH3OH), and the vanillin-concentrated sulfuric acid reaction (TLC) is reddish brown. The FeCl3 color reaction is positive, indicating that it contains phenolic hydroxyl groups. The UV spectrum has maximum absorption at 294nm and 224nm. The IR spectrum shows that the hydroxyl group (3351cm -1 ), carbonyl (1618cm -1 ) and benzene ring (1493cm -1 and 1449cm -1 ) characteristic absorption; HR-ESI-MS analysis results are shown in Fig.29 HR-ESI-MS spectrum showed quasi-molecular ion peak m / z 410.1242[M+H] + (calcd for C 22 H 20 NO7: 410.1240), the molecular formula of the compound can be determined to be C 22 H 19 NO7.
[0122] like Fig.30 As shown, the compound 1 H NMR spectrum (600 MHz, CD3OD) showed one aldehyde hydrogen signal [δ H 9.30 (1H, s, H-6")], 1 group of benzene ring hydrogen signals [δ H 6.77 (1H, s, H-6'), 6.38 (1H, s, H-3'), 5.86 (1H, d, J = 2.3 Hz, H-6) and 5.85 (1H, d, J = 2.0 Hz, H-8)] and two olefin hydrogen signals [δ H 6.84 (1H, t, J=3.1Hz, H-4”) and 5.87 (1H, d, J=2.9Hz, H-3”)].
[0123] like Fig.31 As shown, the compound 13 C NMR spectrum (150 MHz, CD3OD) showed 22 carbon signals, which, combined with DEPT135° spectrum, suggested that one of them was a keto carbonyl carbon signal [δ C 198.3 (C-4)], one aldehyde carbon signal [δ C 177.9 (C-6")], 3 methylene signals [δ C 69.1 (C-2), 26.6 (C-9) and 27.1 (C-1”)]. In addition, 12 benzene ring carbon signals were also shown [δ C166.5 (C-7), 163.8 (C-5), 162.8 (C-8a), 154.6 (C-2'), 154.2 (C-4'), 132.1 (C-6'), 114.5 (C-1'), 115.5 (C-5'), 102.4 (C-3'), 101.2 (C-4a), 95.9 (C-6) and 94.7 (C-8)] and two pairs of double bond carbon signals [δ C 142.6 (C-2”) and 109.3 (C-3”), 131.6 (C-5”) and 121.5 (C-4”)].
[0124] according to 1 H NMR, 13 C NMR, 1 H- 1 For information on H COSY, HSQC, and HMBC spectra, see Figure 30-Figure 34 .exist 1 H- 1 In the H COSY spectrum, two groups of proton coupling systems can be observed, namely: δ H 4.23(H-2a), 2.43 (H-9b) and
[0125] In the HMBC spectrum, δ H 4.23 (H-2a), 4.08 (H-2b) and δ C 198.3(C-4) / 162.8(C-8a),δ H 2.96(H-9a), 2.43(H-9b) and δ C 69.1(C-2) / 132.1(C-6') / 154.6(C-2') have long-range correlations, forming a high isoflavone skeleton. In addition, there are 6 carbon atoms that are not assigned. According to δ H 5.87(H-3") and δ C 131.6(C-5”),δ H 6.84(H-4") and δ C 142.6 (C-2"), respectively, have long-range correlations, and considering the size of the chemical shift, it is speculated that the structure contains a pyrrole ring. H 3.72(H-1") and δ C The long-range correlation of 132.1 (C-6') / 154.2 (C-4') / 109.3 (C-3") shows that the 5-position of the pyrrole ring is connected to the 5'-position of the homoisoflavonoid B ring through 1"-CH2. H 9.30(H-6") and δ C131.6 (C-5") has a relevant relationship, so it is determined that the aldehyde group is connected to the 2-position of the pyrrole ring.
[0126] In summary, it can be determined that V is a high isoflavone alkaloid with another novel skeleton structure, and its planar structure is as follows:
[0127]
[0128] When determining its absolute configuration, we found that its CD spectrum had no obvious cotton effect and the optical rotation value was close to zero. We used Chiral NQ(2)-RH 5μ chiral analysis column to analyze it. The chromatographic conditions were: CH3CN:H2O=35:65, 0.7mL / min. We found that it was a racemic body Va and Vb with a peak area ratio of 1:1. The chiral analysis chromatogram is shown in Fig.35 .
[0129] The structural formula of the compound is:
[0130] Test Example 6
[0131] Characterization of the compound shown in Formula VI:
[0132] The compound is a white powder (CH3OH). The vanillin-concentrated sulfuric acid reaction (TLC) is reddish brown. The FeCl3 color reaction is positive, indicating that it contains phenolic hydroxyl groups. The UV spectrum has maximum absorption at 294nm and 224nm. The IR spectrum shows that the hydroxyl group (3223cm -1 ), carbonyl (1615cm -1 ) and benzene ring (1512cm -1 , 1482cm -1 and 1448cm -1 ) characteristic absorption; HR-ESI-MS analysis results are shown in Fig.36 HR-ESI-MS spectrum showed quasi-molecular ion peak m / z 496.1601[M+H] + (calcd for C 26 H 26 NO9: 496.1608), the molecular formula of the compound can be determined to be C 26 H 25 NO9.
[0133] like Fig.37 As shown, the compound 1 H NMR spectrum (600 MHz, CD3OD) showed one aldehyde hydrogen signal [δ H 9.30 (1H, s, H-6")], 1 group of benzene ring hydrogen signals [δ H6.69 (1H, s, H-6'), 6.37 (1H, s, H-3'), 5.85 (1H, d, J = 2.2 Hz, H-6) and 5.81 (1H, d, J = 2.2 Hz, H-8)] and two olefin hydrogen signals [δ H 6.96 (1H, d, J = 4.1 Hz, H-4") and 5.98 (1H, d, J = 4.1 Hz, H-3")].
[0134] like Fig.38 As shown, the 13C NMR spectrum (150 MHz, CD3OD) of the compound showed 26 carbon signals, which, combined with the DEPT135° spectrum, suggested that one of them was a keto carbonyl carbon signal [δ C 200.1(C-4)], one aldehyde carbon signal [δ C 179.8 (C-6")] and one carboxyl carbon signal [δ C 176.4 (C-10")], 6 methylene signals [δ C 70.7 (C-2), 45.5 (C-7"), 31.9 (C-9"), 28.2 (C-9), 27.3 (C-8") and 26.6 (C-1")]. In addition, 12 benzene ring carbon signals were also shown [δ C 168.0 (C-7), 165.7 (C-5), 164.8 (C-8a), 156.3 (C-2'), 155.6 (C-4'), 133.5 (C-6'), 116.9 (C-1'), 116.3 (C-5'), 103.5 (C-3'), 102.9 (C-4a), 97.0 (C-6) and 95.7 (C-8)] and two pairs of double bond carbon signals [δ C 146.8 (C-2”) and 111.9 (C-3”), 132.6 (C-5”) and 127.4 (C-4”)].
[0135] according to 1 H NMR, 13 C NMR, 1 H- 1 For information on H COSY, HSQC, and HMBC spectra, see Figure 37-Figure 41 .exist 1 H- 1 In the H COSY spectrum, three groups of proton coupling systems can be observed, namely: δ H 4.22(H-2a), 2.55(H-9b), and
[0136] In the HMBC spectrum, δ H4.22 (H-2a), 4.06 (H-2b) and δ C 200.1(C-4) / 164.8(C-8a),δ H 3.10(H-9a), 2.55(H-9b) and δ C 70.7(C-2) / 133.5(C-6') / 156.3(C-2') have long-range correlations, forming a high isoflavone skeleton. In addition, there are 10 carbon atoms that are not assigned. H 5.98(H-3”) and δ C 132.6(C-5”),δ H 6.96(H-4") and δ C 146.8(C-2") and δ H 4.35(H-7") and δ C 146.8 (C-2") / 132.6 (C-5") have long-range correlations, and considering the size of the chemical shift, it is speculated that the structure contains a pyrrole ring substituted on the N. 1 H- 1 H COSY spectrum The proton coupling system and δ H 1.88(H-8") and δ C The long-range correlation of 176.4 (C-10") confirmed that the substituent on N was butyric acid. H 3.87(H-1") and δ C The long-range correlation of 133.5 (C-6') / 155.6 (C-4') / 111.9 (C-3") shows that the 5-position of the pyrrole ring is connected to the 5'-position of the homoisoflavonoid B ring through 1"-CH2. H 9.30(H-6") and δ C 132.6 (C-5") has a relevant relationship, so it is determined that the aldehyde group is connected to the 2-position of the pyrrole ring.
[0137] In summary, it can be determined that compound VI is a high isoflavone alkaloid enantiomer with the same skeleton as V, and its planar structure is as follows:
[0138]
[0139] When determining its absolute configuration, we found that its CD spectrum had no obvious cotton effect and the optical rotation value was close to zero. We used Chiral NQ(2)-RH 5μ chiral analysis column to analyze it and found that it was a 1:1 racemic isomer VIa and VIb. The chiral analysis chromatogram is shown in Fig.42We successfully separated it using a Chiral NQ(2)-RH 5μ preparative column. In order to determine its absolute configuration, we used the density functional theory (DFT) method of Guassian 09 software to calculate the theoretical CD spectra of the two absolute configurations of the compound and compared them with the measured CD spectra of the compound (see Fig.43 ), further confirming that the absolute configuration of the chiral center of VIa is S, and the specific rotation is On the contrary, the absolute configuration of VIb is R, and its specific rotation is In summary, the structures of compounds VIa and VIb were determined to be high isoflavone alkaloids with novel skeleton structures.
[0140] The structural formula of the compound is:
[0141] Test Example 7
[0142] α-Glucosidase inhibitory activity assay:
[0143] The compound was first dissolved in DMSO and then diluted to the required concentration gradient with phosphate buffered saline (PBS, pH = 7.2-7.4). At the same time, p-NPG was dissolved in DMSO and diluted to 1 mM with PBS. In addition, α-glucosidase was dissolved in PBS and diluted to 0.5 U / mL with PBS. In a 96-well plate, 50 μL PBS, 50 μL sample, and 50 μL α-glucosidase were added to the experimental wells; 100 μL PBS, 50 μL α-glucosidase were added to the control wells; 100 μL PBS and 50 μL sample were added to the blank wells. After the 96-well plate was incubated in a 37°C constant temperature water bath for 10 minutes, 50 μL p-NPG was added to each well, and then incubated at 37°C for 30 minutes, and its OD value was measured at 410 nm with an enzyme reader. Acarbose was used as the positive control for this experiment.
[0144] The compounds represented by formula I, formula II, formula III, formula IV, formula V and formula VI isolated from Polygonatum cyrtonema were screened for α-glucosidase inhibitory activity, and the results are shown in Table 1.
[0145] Table 1
[0146] Compound <![CDATA[IC 50 (μM)]]> The compound shown in formula I >50 The compound shown in formula II >50 The compound shown in formula III >50 The compound shown in formula IV 16.87±3.35 The compound represented by formula V 6.03±0.42 The compound shown in formula VI 15.13±3.43 Acarbose 0.53±0.32
[0147] The data in Table 1 show that, by comparison with the positive drug acarbose, the compound represented by Formula IV, the compound represented by Formula V and the compound represented by Formula VI all have strong α-glucosidase inhibitory activity, have the potential to lower blood sugar, and can be used to prepare drugs for preventing or treating diabetes.
[0148] Test Example 8
[0149] ABTS free radical scavenging activity assay:
[0150] The ABTS free radical scavenging ability test kit was purchased from Beijing Solebow Technology Co., Ltd. The kit includes 6 reagents including extraction solution, reagents 1 to 5, and reagents 2 to 4 were pre-treated according to the instructions.
[0151] Determination steps:
[0152] Dissolve the sample fully with the extract, and use the extract to prepare the corresponding concentration gradient. Add the following reagents to a 96-well plate: add 10 μL of sample extract, 20 μL of reagent four working solution and 170 μL of ABTS working solution to the sample well; add 10 μL of sample extract and 190 μL of reagent one to the control well; add 10 μL of water, 20 μL of reagent four working solution and 170 μL of ABTS working solution to the blank well; add 10 μL of vitamin C solution of different concentrations, 20 μL of reagent four working solution and 170 μL of ABTS working solution to the positive control well. After fully mixing, let stand at room temperature away from light for 8 minutes, and measure its absorbance at 410 nm. Prepare a standard curve based on the concentration gradient of the sample and vitamin C, and calculate the IC 50 The results are shown in Table 2. The calculation formula for the clearance rate is as follows:
[0153] Positive drug ABTS clearance rate (%) = [(A blank –A positive control ) / A blank ]×100%;
[0154] Sample ABTS clearance rate (%) = [1-(A sample –A control ) / A blank ]×100%;
[0155] A sample is the absorbance of the sample well; A control is the absorbance of the control well; A blank is the absorbance of the blank well; A positive control is the absorbance of the positive control well.
[0156] Table 2
[0157] Compound <![CDATA[ABTS radical scavenging ability IC 50 (μM)]]> The compound shown in formula I >100 The compound shown in formula II 12.40±0.11 The compound shown in formula III 12.60±0.35 The compound shown in formula IV 19.91±0.93 The compound represented by formula V 26.64±3.05 The compound shown in formula VI 28.46±0.07 Vitamin C 23.58±1.32
[0158] The data in Table 2 show that the compounds of Formula II, Formula III and Formula IV have stronger scavenging abilities against ABTS free radicals than the control drug vitamin C. Therefore, the compounds of Formula II, Formula III and Formula IV have good antioxidant abilities and can be used to prepare antioxidant drugs.
[0159] Test Example 9
[0160] DPPH free radical scavenging activity assay:
[0161] The DPPH free radical scavenging ability test kit was purchased from Beijing Solebow Technology Co., Ltd. The kit includes 4 reagents including extract, reagents 1 to 3, and reagents 2 and 3 are pre-treated according to the instructions.
[0162] Determination steps:
[0163] Dissolve the sample fully with the extract and dilute it with the extract to the required concentration gradient. Add the following reagents to the 96-well plate: add 10 μL of sample extract and 190 μL of working solution to the test well; add 10 μL of sample extract and 190 μL of reagent 1 to the control well; add 10 μL of extract and 190 μL of working solution to the blank well; add 10 μL of vitamin C standard solution and 190 μL of working solution to the positive control tube. Mix well and let stand at room temperature for 30 minutes, and measure its absorbance at 515 nm. Prepare a standard curve based on the concentration gradient of the sample and vitamin C, and calculate the IC 50 The results are shown in Table 3. The calculation formula for the clearance rate is as follows:
[0164] Positive drug DPPH clearance rate (%) = [(A blank –A positive control ) / A blank ]×100%;
[0165] Sample DPPH removal rate (%) = [1-(A sample –A control ) / A blank ]×100%;
[0166] A sample is the absorbance of the sample well; A control is the absorbance of the control well; A blank is the absorbance of the blank well; A positive control is the absorbance of the positive control well.
[0167] Table 3
[0168] Compound <![CDATA[IC value for DPPH radical scavenging ability 50 (μM)]]> The compound shown in formula I >300 The compound shown in formula II 97.02 The compound shown in formula III >300 The compound shown in formula IV 217.45 The compound represented by formula V 198.52 The compound shown in formula VI 187.98 Vitamin C 24.14±0.30
[0169] The data in Table 3 show that the compound represented by Formula I, the compound represented by Formula II, the compound represented by Formula III, the compound represented by Formula IV, the compound represented by Formula V and the compound represented by Formula VI all have scavenging activity against DPPH free radicals.
[0170] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.
Claims
1. A flavonoid alkaloid extracted from Polygonatum cyrtonema, It is characterized in that The flavonoid alkaloids are selected from (Formula II), (Formula III), (Formula IV), (Formula V) and At least one of (Formula VI).
2. The method for extracting flavonoid alkaloids as claimed in claim 1, It is characterized in that The steps include: (1) Mixing Polygonatum cyrtonema with an extraction solvent I to obtain an extract, and concentrating the extract to obtain a total extract; (2) dispersing the total extract with water, extracting with petroleum ether, ethyl acetate and n-butanol, and concentrating to obtain a petroleum ether extract, an ethyl acetate extract and a n-butanol extract; (3) separating and treating the ethyl acetate extract to obtain the flavonoid alkaloids; In step (3), the separation process includes: S1, separating the ethyl acetate extract through a silica gel column, and gradient eluting with a dichloromethane-methanol mixture to obtain eleven components, Fr.A-Fr.K; S2, purifying the Fr.E component and the Fr.F component; In step S2, the purification includes: The Fr.E component is separated by silica gel column III-1, and gradient eluted with a dichloromethane-methanol mixture to obtain eight components Fr.E.1-Fr.E.8; the Fr.E.5 component is separated by gel column III-2, and isocratically eluted with a dichloromethane-methanol mixture to obtain four components Fr.E.5.1-Fr.E.5.4; the Fr.E.5.4 component is separated by semi-preparative high performance liquid phase III-3, and gradient eluted with an acetonitrile-water mixture to obtain the compound of formula V; The Fr.F component was separated by silica gel column IV-1, and gradient eluted with dichloromethane-methanol mixture to obtain seventeen components Fr.F.1-Fr.F.17; the Fr.F.2 component was separated by reverse phase column IV-2, and gradient eluted with methanol-water mixture to obtain sixteen components Fr.F.2.1-Fr.F.2.16; the Fr.F.2.14 component was separated by gel column IV-3, isocratically eluted with dichloromethane-methanol mixture, and then separated by semi-preparative high performance liquid phase IV-4, and isocratically eluted with acetonitrile-water mixture to obtain the compound of formula VI; the Fr.F.2.10 component was separated by gel column IV-3, isocratically eluted with dichloromethane-methanol mixture, and then separated by semi-preparative high performance liquid phase IV-4, and isocratically eluted with acetonitrile-water mixture to obtain the compound of formula VI. Column separation IV-5, after isocratic elution with dichloromethane-methanol, continued to semi-preparative high-performance liquid separation IV-6, and isocratic elution with acetonitrile-water mixture to obtain the compound of formula II; the Fr.F.17 component was separated by reverse phase column IV-7, and gradient eluted with methanol-water solution to obtain twenty components Fr.F.17.1-Fr.F.17.20; the Fr.F.17.14 component was separated by gel column IV-8, after isocratic elution with dichloromethane-methanol mixture, continued to semi-preparative high-performance liquid separation IV-9, and isocratic elution with acetonitrile-water mixture to obtain the compound of formula III and the compound of formula IV.
3. The extraction method according to claim 2, It is characterized in that The extraction method further comprises: before the mixing in step (1), drying and crushing the Polygonatum cyrtonema.
4. The extraction method according to claim 2, It is characterized in that In step (1), the extraction solvent I is an ethanol-water solution.
5. The extraction method according to claim 4, It is characterized in that The volume ratio of ethanol to water in the extraction solvent I is 3-9:
1.
6. The extraction method according to claim 2, It is characterized in that In step (1), the extraction method is percolation extraction.
7. The extraction method according to claim 6, It is characterized in that The number of times of the percolation extraction is 3-6 times, and the conditions of each percolation extraction include: temperature of 20-30° C. and time of 3-4 days.
8. The extraction method according to any one of claims 2 to 7, It is characterized in that In step (2), the weight ratio of the total extract to the water is 1:10-20.
9. The extraction method according to claim 8, It is characterized in that Relative to 1g of the total extract, the amount of petroleum ether is 1-3g, the amount of ethyl acetate is 1-3g, and the amount of n-butanol is 1-3g.
10. Use of the flavonoid alkaloids extracted from Polygonatum cyrtonema according to claim 1 or the flavonoid alkaloids extracted by the extraction method according to any one of claims 2 to 9 in the preparation of therapeutic or preventive antioxidant drugs.
11. Use of the flavonoid alkaloids of formula IV, formula V, and formula VI extracted from the Polygonatum cyrtonema according to claim 1 or the flavonoid alkaloids of formula IV, formula V, and formula VI obtained by the extraction method according to any one of claims 2 to 9 in the preparation of drugs for treating or preventing diabetes.
